ExpressIon of her2/neu in locally advanced bladder cancer: Implication for a molecular targeted therapy;Die her2/neu-expression beim lokal fortgeschrittenen harnblasenkarzinom: Ansatz für eine molekulare therapie?

Aktuelle Urologie

Volumn 36, Issue 5, 2005, Pages 423-429

  Wulfing C ^a   Von Struensee, D ^a   Bierer, S ^a   Bogemann M ^a   Hertle, L ^a   Eltze, E ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Bladder cancer; c erbB 2 receptor; Immunohistochemistry; Prognosis; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLADDER; BLADDER TUMOR; CANCER STAGING; COMPARATIVE STUDY; CYSTECTOMY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROTO ONCOGENE; STATISTICAL ANALYSIS; SURVIVAL; TIME; TRANSITIONAL CELL CARCINOMA; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TIME FACTORS; UP-REGULATION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 26244436607     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830253     Document Type: Article

References (32)

1. Bankfalvi A, Simon R, Brandt B, Bürger H, Vollmer I, Dockhorn-Dworniczak B, Lelle RJ, Böcker W. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 2000; 37: 411-419
2. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001; 37 Suppl: 18-24
3. Coogan CL, Estrada CR, Kapur S, Bloom KJ. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004; 63: 786-790
4. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972; 34: 187-220
5. Evans AJ, Pinder SE, Ellis IO, Sibbering DM, Elston CW, Poller DN, Wilson AR. Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team. Clin Radiol 1994; 49: 559-562
6. Hollywood DP, Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 1993; 2: 2369-2375
7. Jimenez RE, Hussain M, Bianco Jr FJ, Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood Jr DP, Grignon DJ. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7: 2440-2447
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
9. Kee KH, Lee MJ, Ro JY. Oncoprotein changes in the flat lesions with atypia and invasive neoplasms of the urinary bladder. Oncol Rep 2001; 8: 579-583
10. Krüger S, Weitsch G, Bütner H, Matthiensen A, Bömer T, Marquardt T, Sayk F, Feller AC, Böhle A. Her2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002; 102: 514-518
11. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001; 28 Suppl 16: 27-32
12. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004; 40: 56-63
13. Lee SE, Chow NH, Chi YC, Tzai TS, Yang WH, Lin SN. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 1994; 14: 1317-1324
14. Lonn U, Lonn S, Friberg S, Nilsson B, Silfversward C, Stenkvist B. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995; 1: 1189-1194
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Chancer Chemother Rep 1966; 50: 163-170
16. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-1367
17. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000; 27 Suppl 9: 13-19
18. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5: 953-962
19. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325
20. Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudat F, Waldman F. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993; 53: 2199-2203
21. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935
22. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182
23. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712
24. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
25. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19: 666-675
26. Suo Z, Holm R, Nesland JM. Squamous cell carcinomas, an immunohistochemical and ultrastructural study. Anticancer Res 1992; 12: 2025-2031
27. Thor A. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? J Natl Cancer Inst 2001; 15: 1120-1121
28. Tsai YS, Tzai TS, Chow NH, Yang WH, Tong YC, Lin JS, Chang CC, Cheng HL, Lin YM. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. Urol Int 2003; 71: 262-270
29. Underwood M, Bartlett J, Reeves J, Gardiner DS, Scott R, Cooke T. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995; 55: 2422-2430
30. Vijver MJ van de, Mooi WJ, Wisman P, Peterse JL, Nusse R. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene 1988; 2: 175-178
31. Wülfing C, Eltze E, Struensee D von, Wülfing P, Hertle L, Piechota H. Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol 2004; 45: 46-52
32. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230-234